CEO Scott Plesha will present and conduct one-on-one meetings at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The company is focused on a portfolio of cutaneous infectious disease products, including ZELSUVMI (berdazimer) gel, 10.3%, for molluscum contagiosum. ZELSUVMI has seen growth with over 20,000 units dispensed from July 2025 through April 2026. The company has acquired two additional FDA-approved products: XEPI (ozenoxacin) for impetigo and XEGLYZE (abametapir) for head lice. Commercial launches for XEPI and XEGLYZE are anticipated in early 2027 and mid-2027, respectively.